Time Trends in the Incidence and Treatment of Extra-Abdominal and Abdominal Aggressive Fibromatosis: A Population-Based Study

Annals of Surgical Oncology

Volumn 22, Issue 9, 2015, Pages 2817-2823

  van Broekhoven, Danique L M ^a   Grünhagen, Dirk J ^a   den Bakker, Michael A ^b   van Dalen, Thijs ^c   Verhoef, Cornelis ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b Maasstad Hospital   (Netherlands)

^c DEPARTMENT OF SURGERY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL FIBROMATOSIS; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PATIENT; CANCER REGISTRY; CANCER STATISTICS; CANCER SURGERY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; EXTREMITY FIBROMATOSIS; FEMALE; FIBROMATOSIS; HEAD AND NECK FIBROMATOSIS; HEAD AND NECK TUMOR; HISTOPATHOLOGY; HUMAN; LIMB TUMOR; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; SEX DIFFERENCE; TIME; TREND STUDY; TRUNK FIBROMATOSIS; TUMOR BIOPSY; TUMOR LOCALIZATION; VERY ELDERLY; FIBROMATOSIS, ABDOMINAL; FIBROMATOSIS, AGGRESSIVE; INCIDENCE; MIDDLE AGED; NETHERLANDS; PATHOLOGY; PROGNOSIS; TIME FACTOR; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FIBROMATOSIS, ABDOMINAL; FIBROMATOSIS, AGGRESSIVE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; PROGNOSIS; TIME FACTORS; YOUNG ADULT;

EID: 84938952826     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4632-y     Document Type: Article

References (32)

1. Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol. 1997;151(2):329–34.
2. Tejpar S, Michils G, Denys H, et al. Analysis of Wnt/Beta catenin signalling in desmoid tumors. Acta Gastroenterol Belg. 2005;68(1):5–9.
3. Lips DJ, Barker N, Clevers H, Hennipman A. The role of APC and beta-catenin in the aetiology of aggressive fibromatoses (desmoid tumors). Eur J Surg Oncol. 2009;35:3–10.
4. Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F, eds. Tumours of soft tissue and bone: pathology and genetics. World Health Organization classification of tumours, 4th edn. Lyon: IARC Press; 2013.
5. Devata S, Chugh R. Desmoid tumors: a comprehensive review of the evolving biology, unpredictable behavior, and myriad of management options. Hematol Oncol Chil North Am. 2013;27:989–1005.
6. Reitamo JJ, Häyry P, Nykyri E, Saxén E. The desmoid tumor. I. Incidence, sex, age, and anatomical distribution in the Finnish population. Am J Clin Pathol. 1982;77(6):665–73.
7. Häyry P, Reitamo JJ, Tötterman S, Hopfner-Hallikainen D, Sivula A. The desmoid tumor. II. Analysis of factors possibly contributing to the etiology and growth behavior. Am J Clin Pathol. 1982;77(6):674–80.
8. Häyry P, Reitamo JJ, Vihko R, et al. The desmoid tumor. III. A biochemical and genetic analysis. Am J Clin Pathol. 1982;77(6):681–5.
9. Nieuwenhuis MH, Casparie M, Mathus-Vliegen LM, Dekkers OM, Hogendoorn PC, Vasen HF. A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer. 2011;129(1):256–61.
10. Robanus-Maandag E, Bosch C, Amini-Nik S, et al. Familial adenomatous polyposis-associated desmoids display significantly more genetic changes than sporadic desmoids. PLoS One. 2011;6(9):e24354.
11. Durno C, Monga N, Bapat B, Berk T, Cohen Z, Gallinger S. Does early colectomy increase desmoid risk in familial adenomatous polyposis? Clin Gastroenterol Hepatol. 2007;5(10):1190–4.
12. Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2008;71:441–7.
13. Ballo MT, Zagers GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999;17:158–67.
14. Baumert BG, Spahr MO, Van Hochsetter A, et al. The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the rare cancer network. Radiat Oncol. 2007;2:12.
15. van Broekhoven DLM, Verhoef C, Elias SG, et al. Local recurrence after surgery for primary extra-abdominal desmoid-type fibromatosis. Br J Surg. 2013;100(9):1214–1219.
16. http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf, version 1; 2013. Accessed Sept 2014.
17. ESMO Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:92–9.
18. Keus RB, Nout RA, Blay JY, et al. Results of a phase II pilot study for moderate dose radiotherapy for inoperable desmoid-type fibromatosis: an EORTC STBSG and ROG study (EORTC 62991-22998). Ann Oncol. 2013;24(10):2672–6.
19. van Broekhoven DLM, Deroose JP, Bonvalot S, et al. Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis. Br J Surg. 2014;101(13):1674–80.
20. Garbay D, Le Cesne A, Penel N, et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol. 2012;23:182–6.
21. Bocale D, Rotelli MT, Cavallini A, et al. Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review. Colorectal Dis. 2011;13(12):e388–95.
22. Penel N, Le Cesne A, Bui BN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol. 2011;22(2):452–7.
23. Casparie M, Tiebosch ATMG, Burger G, Blauwgeers H, Pol A, van de Krieken JHJM, van Meijer GA. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histiopathology and cytopathology data network and archive. Cell Oncol. 2007;29:19–24.
24. Centraal Bureau voor de Statistiek, Den Haag/Heerlen 2014. Available in English from: http://www.cbs.nl/en-GB/menu/home/default.htm?Languageswitch=on.
25. Fletcher CDM, Unni KK, Mertens F editors. Tumours of soft tissue and bone: pathology and genetics. World Health Organization classification of tumours, 3rd edn. Lyon: IARC Press; 2002.
26. Kloosterboer FM, Siesling S. Kwaliteit van kankerzorg in Nederland 2014. Bijlage D. Deelrapportage voor wekedelensarcomen. Available at: https://www.iknl.nl/docs/default-source/KIB-rapportages/rapportage-wekedelensarcomen-sck-rapport.pdf?sfvrsn=2.
27. Montgomery E, Torbenson MS, Kaushal M, Fisher C, Abraham SC. Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. Am J Surg Pathol. 2002;26(10):1296–301.
28. Cheon SS, Cheah AY, Turley S, et al. Beta-catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci USA. 2002;99(10):6973–8.
29. Bhattacharya B, Dilworth HP, Iacobuzio-Donahue C, et al. Nuclear beta-catenin expression distinguished deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol. 2005;29(5):653–9.
30. Gronchi A, Colombo C, Le Péchoux C, et al. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplams—a position paper from the Italian and the French Sarcoma Group. Ann Oncol. 2014;25(3):578–83.
31. Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16(9):2587–93.
32. Kasper B. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients’ and professionals’ expertise—a European Organisation for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) and Sarcoma Patients Euronet (SPAEN) Initiative. Eur J Cancer. 2015;51(2):127–36.